2021 / 03

Next Paper
DOI: 10.24075/brsmu.2021.031

ORIGINAL RESEARCH

Benzimidazole derivative as antitumor drug against experimentally induced lung carcinoma

Komarova EF1,2, Zhukovskaya ON3, Lukbanova EA, Yengibaryan MA, Vashenko LN1, Kharagezov DA1, Pozdnyakova VV, Ushakova ND, Shatova YuS, Przhedetsky YuV
About authors

1 National Medical Research Center of Oncology, Rostov-on-Don, Russia

2 Rostov State Medical University, Rostov-on-Don, Russia

3 Research Institute for Physical and Organic Chemistry of Southern Federal University, Rostov-on-Don, Russia

Correspondence should be addressed: Ekaterina A. Lukbanova
Azovskaya, 163, 346783, Azov; ur.xednay@ajaksramas.aytak

About paper

Funding: synthesis of the tested compound was supported by the Russian Ministry of Science and Higher Education under the state assignment for the Southern Federal University, 2020, Project FENW-2020-0031 (0852-2020-0031). In vivo experiments were part of the state assignment Study of antitumor activity of pharmacological substances in vivo and in vitro (121031100253-3).

Author contributions: Komarova EF proposed the design, conducted the experiment and wrote the draft version of the manuscript; Zhukovskaya ON synthesized the tested compound and edited the manuscript; Lukbanova EA conducted the experiment and contributed to writing the manuscript; Yengibaryan MA edited the manuscript; Vashenko LN proposed the concept and design for the study, edited the manuscript; Kharagezov DA contributed to writing the manuscript; Pozdnyakova VV performed statistical analysis; Ushakova ND proposed the concept and design for the study; Shatova YuS prepared the list of references and edited the manuscript; Przhedetsky YuV performed technical editing.

Compliance with ethical standards: the study was approved by the Ethics Committee of National Medical Research Center for Oncology (Protocol № 18 dated September 10, 2015); the experiment complied with the European Convention for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes.

Received: 2021-06-01 Accepted: 2021-06-15 Published online: 2021-06-25
|
  1. Kit OI, Shaposhnikov AV, Zlatnik EYu, Nikipelova EA, Novikova IA. Mestnyj kletochnyj immunitet pri adenokarcinome i polipah tolstoj kishki. Sibirskoe medicinskoe obozrenie. 2012; 4 (76): 11–16. Russian.
  2. Kit OI, Franciyanc EM, Nikipelova EA, Komarova EF, Kozlova LS, Tavarjan IS, i dr. Izmenenija markerov proliferacii, neoangiogeneza i sistemy aktivacii plazminogena v tkani raka prjamoj kishki. Jeksperimental'naja i klinicheskaja gastrojenterologija. 2015; 2 (114): 40–45. Russian.
  3. Bashraheel SS, Domling A, Goda SK. Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine. Biomed Pharmacother. 2020; 125: 110009.
  4. Silva-Santisteban MC, Westwood IM, Boxall K. Fragment-based screening maps inhibitor interactions in the ATP-binding site of checkpoint kinase 2. PLoS One. 2013; 8 (6): e65689.
  5. Penning TD, Zhu G-D, Gandhi VB, Gong J, Liu X, Shi Y, at al. Discovery of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor 2-[(R)-2-Methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the Treatment of Cancer. J Med Chem. 2009; 52: 514.
  6. Ali I, Lone MN, Aboul-Enein H.Y. Imidazoles as potential anticancer agents. Medchemcomm. 2017; 8 (9): 1742–73.
  7. Torres FC, Garcia-Rubino ME, Lozano-Lopez C, Kawano DF, Eifler-Lima VL, von Poser GL. Imidazoles and benzimidazoles as tubulin-modulators for anti-cancer therapy. Curr Med Chem. 2015; 14: 306–18.
  8. Khattab M. Theoretical study of the geometric and electronic characterization of carbendazim-based drug (Nocodazole). Heliyon. 2020; 6 (6): e04055.
  9. Blaszczak-Swiatkiewicz K, Olszewska P, Mikiciuk-Olasik Е. Biological approach of anticancer activity of new benzimidazole derivatives. Pharmacological Reports. 2014; 66 (1): 100–6.
  10. Marcian E, Dort V, Hong H, Wang H, Nino CA, Lombardi RL. Discovery of Bifunctional Oncogenic Target Inhibitors against Allosteric Mitogen-Activated Protein Kinase (MEK1) and Phosphatidylinositol 3-Kinase (PI3K). Journal of Medicinal Chemistry. 2016; 59 (6): 2512–22.
  11. Anisimova VA, Kosolapov VA, Minkin VI, i dr., patentoobladatel'. Digidrobromid 9-(3,4-digidroksifenil)-9-dijetilamiino- jetilimidazo[1,2-a] benzimidazola i farmacevticheskaja kompozicija na ego osnove. Patent RF # 2391979/ 12.05.2008.
  12. Mezhgosudarstvennyj standart. Sistema standartov bezopasnosti truda. Vrednye veshhestva. Klassifikacija i obshhie trebovanija bezopasnosti. GOST 12.1.007-76. Dostupno po ssylke: https:// docs.cntd.ru/document/5200233.
  13. Mironova AN, redaktor. Rukovodstvo po provedeniju doklinicheskih issledovanij lekarstvennyh sredstv. Chast 1, M.: Grif i K, 2013; 944 s.
  14. Kit OI, Komarova EF, Spasov AA, Morkovnik AS, Zhukovskaya ON, Korobejnikova EP, Vanzha LV, Shihljarova AI, Bragina MI, Barteneva TA, Lukbanova EA, Shirnina EA, Zlatnik EJu, Novikova IA, Pozdnjakova VV, Maksimov AJu, Anisimova VA, avtory; FGBU «Nacional'nyj medicinskij issledovatel'skij centr onkologii», patentoobladatel'. Sredstvo dlja ingibirovanija metastazirovanija v legkih. Patent RF # 2632703. 12.12.2016. Russian.
  15. Komarova EF, Shihljarova AI, Bragina MI, Shirnina EA, Barteneva TA, Korobejnikova EP, i dr. Ocenka protivoopuholevoj aktivnosti antioksidanta jenoksifol na modeli melanomy V16 v jeksperimente. Izvestija Vuzov. Severo-Kavkazskij region. Estestvennye nauki. 2017; 3–2: 67–73. Russian.
  16. Aminzadeh–Gohari S, Weber DD, Catalano L, Feichtinger RG, Kofler B, Lang R. Targeting Mitochondria in Melanoma. Biomolecules. 2020; 10 (10): 1395.
  17. Wu M. Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells. Am J Physiol Cell Physiol. 2007; 292: 125–36.
  18. Ohshima K, Morii E. Metabolic Reprogramming of Cancer Cells during Tumor Progression and Metastasis. Metabolites. 2021; 11 (1): 28.
  19. Wei Q, Qian Y, Yu J, Wong CC. Metabolic rewiring in the promotion of cancer metastasis: mechanisms and therapeutic implications. Oncogene. 2020; 39 (39): 6139–56.